Psilocybin Mushroom Laws: What's The Legal Status?

The regulation of psilocybin mushrooms, also known as magic mushrooms, varies across different countries and jurisdictions. Psilocybin and psilocin, the active ingredients in magic mushrooms, are classified as Schedule I drugs under the United Nations 1971 Convention on Psychotropic Substances, which means they are considered to have a high potential for abuse and no recognized medical uses. However, the possession and use of psilocybin mushrooms may be prohibited, regulated, or decriminalized depending on the region. While some places have strict laws against the drug, there is also ambiguity and selective enforcement in some areas. Research and clinical trials are exploring the potential therapeutic benefits of psilocybin, which may influence future regulations.

Psilocybin mushroom legality

The legality of psilocybin mushrooms varies worldwide. Psilocybin and psilocin, the active ingredients in magic mushrooms, are listed as Schedule I drugs under the United Nations 1971 Convention on Psychotropic Substances. Schedule I drugs are defined as drugs with a high potential for abuse or no recognized medical uses. However, psilocybin mushrooms have had numerous medicinal and religious uses in many cultures throughout history and have a significantly lower potential for abuse than other Schedule I drugs.

Psilocybin mushrooms are not regulated by UN treaties, but many countries have some level of prohibition or regulation. For example, the US Psychotropic Substances Act, the UK Misuse of Drugs Act 1971, and the Canadian Controlled Drugs and Substances Act have all been amended to reflect the terms of the 1971 Convention. The possession and use of psilocybin are prohibited under almost all circumstances in these countries and often carry severe legal penalties.

However, there is ambiguity in many national, state, and provincial drug laws regarding the legal status of psilocybin mushrooms, and selective enforcement has been observed in some places. A loophole further complicates the legal situation: the spores of psilocybin mushrooms do not contain the drugs and are legal to possess in many areas, including some jurisdictions in the US, such as California, Georgia, and Idaho, and in Germany.

In recent years, there has been a growing trend towards the legalization or decriminalization of psilocybin mushrooms, particularly in North America. For example, in November 2020, Oregon voters passed a ballot initiative legalizing magic mushrooms for mental health treatment in supervised settings from February 2021. In 2022, Colorado became the second US state to decriminalize psilocybin mushrooms. Additionally, in the same year, the Canadian province of Alberta announced it would regulate and allow the use of psilocybin for medicinal purposes in drug-assisted psychotherapy, with new regulations coming into effect in January 2023.

Medical use

Psilocybin mushrooms, commonly referred to as 'magic mushrooms', have a long history of medicinal and religious use in various cultures worldwide. Despite this, they are currently listed as Schedule I drugs under the United Nations 1971 Convention on Psychotropic Substances, which requires its members to prohibit psilocybin. This classification means that the drug is believed to have a high potential for abuse and no recognised medical use.

However, this characterisation is contested by some. For example, in the United States, several jurisdictions, including the District of Columbia, Oregon, Colorado, Oakland, Denver, Ann Arbor, and Washington, D.C., have moved to decriminalise or legalise the use of psilocybin mushrooms for therapeutic purposes. Oregon, in particular, has become the first jurisdiction in the world to lay out plans for regulating the drug's therapeutic use, with plans to open legal psilocybin therapy centres. These moves towards decriminalisation and legalisation are driven by a growing body of research suggesting that psilocybin may be effective in treating various mental health disorders, including anxiety, depression, obsessive-compulsive disorder, and problematic substance use.

In Canada, while the possession, sale, and production of psilocybin mushrooms are generally illegal, there are pathways for individuals to legally access the substance for medical purposes. These include clinical trials and Health Canada's Special Access Program. Additionally, in January 2023, the province of Alberta announced that it would regulate and allow the use of psilocybin for medicinal purposes in drug-assisted psychotherapy.

In Australia, as of February 2023, psilocybin has been approved for use in prescription medications for the treatment of PTSD and treatment-resistant depression.

Criminalization

Psilocybin mushrooms, often referred to as "magic mushrooms", are illegal in most parts of the world due to their classification as a Schedule I drug under the United Nations 1971 Convention on Psychotropic Substances. Schedule I drugs are defined as substances with a high potential for abuse and no recognised medical use. This classification is reflected in various national drug laws, such as the US Psychotropic Substances Act, the UK Misuse of Drugs Act 1971, the Canadian Controlled Drugs and Substances Act, and similar legislation in Australia and Japan. These laws typically prohibit the possession, use, sale, and production of psilocybin mushrooms, with severe legal penalties for non-compliance.

In the United States, the federal law specifically banning psilocybin and psilocin, the two primary psychoactive compounds in magic mushrooms, was enacted in 1968 as an amendment to the federal Food, Drug and Cosmetic Act. This law was intended to regulate the unlicensed possession, manufacture, or sale of hallucinogenic drugs. While the law initially allowed for some exemptions, most US state courts have since considered mushrooms containing these substances to be illegal "containers" of illicit drugs.

However, there has been a recent trend towards decriminalisation and regulated use of psilocybin mushrooms in some jurisdictions. For example, in November 2020, the District of Columbia passed Initiative 81, also known as the Entheogenic Plant and Fungus Policy Act of 2020, which allows for the possession and non-profit distribution of psilocybin mushrooms for medicinal purposes. Similarly, in 2022, the Canadian province of Alberta announced that it would regulate and permit the use of psilocybin for drug-assisted psychotherapy, with the new regulations coming into effect in January 2023. Other US states, including Oregon and Colorado, have also taken steps towards decriminalisation or legalisation of psilocybin mushrooms for therapeutic purposes.

Despite these developments, the possession and sale of psilocybin mushroom spores remain illegal in several jurisdictions, including Germany and several US states. This has led to the emergence of an underground economy and social networks supporting the illicit trade of spores and cultivation materials.

While the potential therapeutic benefits of psilocybin mushrooms are being explored in clinical trials, there are currently no approved therapeutic products containing psilocybin in Canada or elsewhere. This means that the safety, efficacy, and quality of such products have not been rigorously assessed or authorised for sale by regulatory authorities.

Possession

Psilocybin mushrooms are not regulated by UN treaties, but many countries have some level of regulation or prohibition in place. The United Nations Convention on Psychotropic Substances, adopted in 1971, requires its members to prohibit psilocybin, and parties to the treaty must restrict the use of the drug to medical and scientific research under strictly controlled conditions.

The possession and use of psilocybin mushrooms are prohibited under almost all circumstances in most countries, and often carries severe legal penalties. However, there are some exceptions and nuances to these regulations. For example, in some jurisdictions, Psilocybe spores are legal to possess and sell because they do not contain psilocybin or psilocin. In other jurisdictions, they are banned due to their use in drug manufacturing. A few places, such as California, Georgia, and Idaho in the United States, and Germany, have specifically prohibited the possession and sale of psilocybin mushroom spores.

In the United States, federal law and most states classify psilocybin as a Schedule I drug, making it illegal to possess, sell, or grow. However, there are some exceptions and ongoing changes to the regulations. Colorado and Oregon have legalized certain uses, and a few cities have deprioritized arrest and prosecution for personal possession. As of January 2025, Colorado is the only state where personal use and private cultivation of small amounts of magic mushrooms are legal for adults over 21, with Oregon licensing "psilocybin service centers" for supervised consumption.

Canada also controls psilocybin and psilocin as psychoactive substances under the Controlled Drugs and Substances Act (CDSA), making the sale, possession, and production of magic mushrooms illegal unless authorized by Health Canada. In 2023, the Canadian province of Alberta announced it would be among the first to regulate and allow the use of psilocybin for medicinal purposes in drug-assisted psychotherapy.

In terms of international regulation, the possession and use of psilocybin are prohibited under almost all circumstances, and it is classified as a hallucinogen with effects similar to LSD.

While the trend towards decriminalization and regulation of psilocybin mushrooms is growing, it is important to note that the possession and use of these substances remain illegal in most places, with severe legal consequences.

Ongoing research

Psilocybin mushrooms, often referred to as "magic mushrooms," are regulated substances that have gained attention for their potential therapeutic benefits, particularly in the field of mental health. While they are generally

Frequently asked questions